ArticleJournal of medical virology2026
Molecular and Phylogenetic Characterization of HTLV-1 Infection in Patients With Hematological Malignancies in the State of Pará, Northern Brazil.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Human T-lymphotropic viruses 1 and 2 (HTLV-1 and HTLV-2) were first isolated from patients with hematological malignancies. This study was the first to investigate the frequency of HTLV-1 and its molecular diversity among patients with hematolymphoid cancers who were treated at a leading reference hospital in Pará, northern Brazil. For this purpose, information from the International Classification of Diseases (ICD), laboratory test records, and peripheral blood samples were obtained. Patients with confirmed diagnosis of leukemia/lymphoma, myeloma, other hematological malignancies, and those under diagnostic investigation were included in the study. Serological screening for anti-HTLV-1/2 antibodies was carried out by ELISA, and infection was confirmed by real-time PCR. PCR-positive samples were sequenced for phylogenetic analysis. Of 329 people assessed, 47.7% were men (157) and 52.3% were women (172). The overall prevalence of HTLV-1 was 1.82% (6/329), with 2.5% (n = 4) in men and 1.2% (n = 2) in women. Phylogenetic analysis of the 5'LTR region (715 bp) of HTLV-1 indicated that the isolates belonged to the Cosmopolitan subtype, Transcontinental subgroup. Positivity among patients with lymphoma was 6.56% (4/61), with one patient diagnosed with Hodgkin lymphoma. Among patients under clinical investigation and with other types of cancer, the prevalence of infection was 1.19% (1/84) and 2.38% (1/42), respectively. A decrease in red blood cell count, hemoglobin, and hematocrit was identified in cancer patients with a negative HTLV diagnosis compared to HTLV-positive patients. Our results highlight the importance of including HTLV-1/2 testing in the routine follow-up of cancer patients, for the sake of existing successful treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.